HBM Healthcare Investments Quarterly Report June 2018

Shareholders’ Meeting of HBM Healthcare Investments approved all proposals by the Board of Directors

High demand by investors for the IPO of the HBM-portfolio company Aptinyx

Invitation to the 17th Ordinary Shareholders' Meeting incl. amended agenda item 9

Amended motion of the Board of Directors for agenda item 9

Amendment to agenda item 9 in the invitation to the 17th Ordinary Shareholders’ Meeting on 25 June 2018

Invitation to the 17th Ordinary Shareholders' Meeting

Publication of Annual Report 2017/2018 and Invitation to the Ordinary Shareholders' Meeting

HBM Healthcare Investments reports a profit of CHF 115.9 million for the 2017/2018 financial year; Portfolio will be enriched with further new investments; Positive outlook for the portfolio allows for a 20 percent increase of the proposed cash…

Eli Lilly announces tender offer for HBM-Portfolio Company ARMO BioSciences for USD 1.6 billion

HBM Healthcare Investments increases net asset value per share (NAV) by 11 percent in the 2017/2018 financial year; Net profit of around CHF 115 million expected; Share price rises by 34 percent

Another successful IPO from HBM Healthcare Investments' portfolio: Homology Medicines raises USD 144 million

HBM Healthcare Investments portfolio company, TandemLife, to be acquired for up to USD 250 million in cash

Successful IPO of HBM-Portfolio Company ARMO BioSciences

A strong third quarter further extended HBM Healthcare Investments’ profit for the first nine months of the 2017/2018 financial year to a total of CHF 85.6 million

Delightful 2017 for HBM Healthcare Investments with 26% value increase of the NAV and 40% gain on the share price

CSL and HBM-Portfolio Company Vitaeris Announce Strategic Partnership with Option to Acquire

Novartis announces tender offer for HBM-Portfolio Company Advanced Accelerator Applications for USD 3.9 billion

HBM Healthcare Investment Half-Year Report September 2017

Y-mAbs Therapeutics closes USD 50 million financing round led by HBM Healthcare Investments

HBM Healthcare Investments announces investment of USD 30 million in Harmony Biosciences

NAV Key Figures as at 30 September 2017

Capital reduction completed

HBM Healthcare Investments Quarterly Report June 2017

NAV Key Figures as at 30 June 2017

Shareholders’ Meeting approved all proposals by the Board of Directors

Publication of Annual Report 2016/2017 and Invitation to the Ordinary Shareholders’ Meeting

Invitation to the 16th ordinary Shareholders’ meeting

Bioverativ acquires HBM-portfolio company True North Therapeutics for up to USD 825 million plus assumed cash

HBM Healthcare Investments generated a profit of CHF 136.8 million for the 2016/2017 financial year and increased net asset value per share by 15.2 percent. Board of Directors proposing an increase in the cash dividend of 30 centimes, to…

HBM Healthcare Investments commits EUR 20 million in growth capital to Switzerland based Amicus SA

HBM Healthcare Investments expects to report a net profit of around CHF 136 million for the financial year 2016/2017 – increase of the net asset value per share of around 15 percent

HBM Healthcare Investments Quarterly Report 2016

Two IPOs from the HBM Healthcare Investments portfolio increase net asset value per HBM-share by CHF 2.30

Net Asset Value per HBM-share of CHF 133.43 as at 31 December 2016

HBM Healthcare Investments Quarterly Report September

HBM Healthcare Investments invests USD 10 million in True North Therapeutics

Rückkauf eigener Aktien zum Zweck der Kapitalherabsetzung

Rachat d’actions propres dans le but d’une réduction de capital (103 KB)

HBM Healthcare Investments launches a new share buy-back programme

Net asset value (NAV) of CHF 139.42 as at 30 September 2016

HBM Healthcare Investments terminates share buy-back programme 2014

Capital reduction completed

HBM Healthcare Investments Quarterly Report June 2016

Shareholders’ Meeting approved all proposals by the Board of Directors

Paratek Pharmaceuticals Announces Positive Phase 3 Results for its Antibiotic Omadacyline

Recommended all share merger of Skyepharma and Vectura becomes effective

Annual Report 2015/2016

Invitation to the 15th Ordinary Shareholders’ Meeting

Publication of Annual Report 2015/2016 and Invitation to the Ordinary Shareholders’ Meeting

HBM Healthcare Investments closes financial year 2015/2016 with earnings of CHF 23 million despite a negative market environment. Unchanged cash dividend of CHF 5.50 per share.

HBM Healthcare Investments closes financial year 2015/2016 with earnings of CHF 23 million despite pronounced market correction in healthcare sector

Skyepharma to merge with Vectura Group

Closing of the sale of Ellipse Technologies to NuVasive

HBM Healthcare Investments adds cancer immunotherapy company ARMO BioSciences to portfolio

HBM Healthcare Investments Quarterly Report December 2015

HBM Healthcare Investments backs Iconic Therapeutics to advance development of a novel, disease modifying approach in retinal diseases

Sale of Ellipse Technologies to NuVasive for an upfront consideration of USD 380 million and a potential additional milestone payment of USD 30 million in cash boosts net asset value per HBM-share by CHF 9.70 (+6.5%)

Strong increase of net assets by CHF 208 million in the quarter leads to a new high of the NAV per HBM-share of CHF 149.76 as at 31 December 2015

Cathay Industrial Biotech to set foundation for further successful corporate development with financing of USD 135 million

HBM Healthcare Investments participates in CHF 60 million financing of Swiss women’s health company ObsEva

HBM Healthcare Investments commits to invest USD 10 Million in clinical-stage company Eiger BioPharmaceuticals

Initial Public Offering of Advanced Accelerator Applications boosts Net Asset Value per HBM share by CHF 5.20 (+4.2%)

HBM Healthcare Investments Quarterly Report September 2015

Net asset value (NAV) of CHF 121.12 as at 30 September 2015

Advanced Accelerator Applications: Detailed Phase 3 Study Results Presented at the European Cancer Congress 2015 Demonstrate that Lutathera® Significantly Improves Progression-Free Survival in Patients with Advanced Midgut Neuroendocrine…

Advanced Accelarator Applications Results from pivotal Phase 3 NETTER-1 Study

Initial Public Offering of Nabriva Therapeutics

Advanced Accelerator Applications’ (AAA) Pivotal Phase 3 NETTER-1 Study of Lutathera® Met Primary Endpoint - Data will be Presented at the European Cancer Congress 2015

Capital reduction completed

Raptor Pharmaceuticals Acquires Rights to QuinsairTM

HBM Healthcare Investments Quarterly Report June 2015

HBM Healthcare Investments AG has closed the books early and has fixed the issue amount of the combined bond tranches at CHF 100 million

HBM Healthcare Investments NAV Key Figures as at 30.6.2015

HBM Healthcare Investments announces the issue of two bond tranches, one with a 6 year and the other with a 8 year term with a minimum issue amount of CHF 50 million each

Shareholders approved all proposals and recommendations by the Board of Directors

Shareholders’ Letter June 2015

Invitation to the 14th ordinary Shareholders’ Meeting on 26 June 2015

HBM Healthcare Investments closed financial year 2014/2015 with a net profit of CHF 257.5 million - Proposed cash dividend of CHF 5.50 per share

Net asset value (NAV) per share of CHF 140.60 as at 31 March 2015

HBM Healthcare Investments Quarterly Report December 2014

NAV Key Figures as at 15 January 2015 / Comment on the impact of foreign exchange rates

HBM Healthcare Investments reports substantial value growth in calendar year 2014

Rückkauf eigener Aktien zum Zweck der Kapitalherabsetzung

Rachat d’actions propres destiné à réduire le capital-actions

Rückkauf eigener Aktien zum Zweck der Kapitalherabsetzung

Paratek Pharmaceuticals completes merger with Transcept Pharmaceuticals

HBM Healthcare Investments launches share buy-back programme

HBM Healthcare Investments takes USD 8 million stake in Vascular Dynamics

Probiodrug accomplishes Initial Public Offering at Amsterdam’s Euronext

Initial Public Offering of Forward Pharma increases Net Asset Value per share by CHF 2.32

HBM Healthcare Investments NAV Key Figures as at 30 September 2014

HBM Healthcare Investments Quarterly Report June 2014

Paratek Pharmaceuticals signs merger agreement with NASDAQ-listed Transcept Pharmaceuticals

HBM Healthcare Investments Key Figures as at 30 June 2014

Shareholders approved all proposals and recommendations by the Board of Directors

Result from share buy-back through the issue of put-options

Shareholders´ letter

Invitation to the 13th Ordinary Shareholders´ Meeting

Media Release: Invitation to the Ordinary Shareholders´ Meeting

PTC Therapeutics receives positive opinion from European Medical Agency for TranslarnaTM

Buy-back of own registered shares for the purpose of capital reduction through the issuance of tradable put options

HBM Healthcare Investments announces terms of share buy-back involving the issue of put options

Ophthotech enters into licensing agreement with Novartis – share price rises more than 20% in after-market trading

HBM Healthcare Investments publishes Annual Report 2013/2014

HBM Healthcare Investments to end “share buy-back programme 2012”

HBM Healthcare Investments shareholders participate in outstanding annual result: issue of put options to accelerate share buy-backs and proposal of a cash dividend of CHF 3.00 per share to the Ordinary Shareholders´ Meeting

Net Asset Value per share of CHF 108.76 as at 31 March 2014

Skyepharma announces £112 million capital increase and launches tender offer for outstanding bonds

HBM Healthcare Investments participates with EUR 20 million in financing round of Advanced Accelerator Applications

Quarterly Report December 2013

Investment in Intercept with spectacular value increase of 647%

HBM Healthcare Investments achieves compelling value increase of 65 percent in the calendar year 2013

HBM Healthcare Investments Quarterly Report September 2013

Ophthotech IPO increases NAV by CHF 4.96 per share (+6.3%)

Ophthotech increases price range for IPO to USD 19-20 per share

Quarterly Report June 2013

Information on Ophthotech IPO

Key Figures (NAV, net assets, net result for the quarter) as as 30 June 2013

Shareholders approved all proposals by the Board of Directors

PTC Therapeutics completes initial public offering

Ophthotech secures financing of USD 175 million for phase-III clinical trial of FovistaTM

Annual Report 2012/2013 and invitation to the ordinary Shareholders’ Meeting

Invitation to the ordinary Shareholders´ Meeting

HBM Healthcare Investments achieves net profit of CHF 67 million for the year and proposes a par-value repayment of CHF 1.50 per share to shareholders´ meeting

Key Figures (NAV, net assets, net result) as at 31.03.2013

Successful IPO for Enanta Pharmaceuticals

HBM Healthcare Investments Quarterly Report December 2012

HBM Healthcare Investments Quarterly Report September 2012

Rachat d’actions propres destiné à réduire le capital-actions

HBM Healthcare Investments starts new share buy-back programme

HBM Healthcare Investments Quarterly Report June 2012

SkyePharma receives approval for flutiform® in Europe

Shareholders’ Meeting approved all proposals by the Board of Directors and Management presents confident outlook

Ophthotech’s novel anti-PDGF combination agent FovistaTM demonstrated superior efficacy over Lucentis® monotherapy in large controlled wet AMD trial

Basilea enters into global agreement with Stiefel, a GlaxoSmithKline company, for Toctino® (alitretinoin)

Nabriva Therapeutics signs Agreement for Collaboration and Option for Sale of the Company

Invitation to the ordinary Shareholders´ Meeting

Annual Report 2011/2012 and invitation to the ordinary Shareholders´ Meeting

HBM BioVentures publishes annual results for 2011/12

HBM BioVentures publishes preliminary results for the fourth quarter and the full financial year 2011/12

Enanta signs significant collaboration agreement with Novartis for Hepatitis C programme

HBM Report Shows Strong M&A Activity in the Pharma Sector

Successful Initial Public Offering of ChemoCentryx

HBM BioVentures Quarterly Report as at 31 December 2011

Promising new approach to the treatment of wet age-related macular degeneration

ChemoCentryx announces details for its planned Initial Public Offering

Vivacta sold to major pharmaceutical company for USD 90 million

ChemoCentryx licenses investigational drug for rheumatoid arthritis to GlaxoSmithKline

Pivotal clinical trial of Lux Biosciences misses endpoint

PTC Therapeutics signs licensing agreement with Roche for Spinal Muscular Atrophy (SMA) Programme (46 KB) 30.11.2011

New CFO at HBM BioVentures

Pacira Pharmaceuticals announces U.S. FDA approval of EXPAREL(TM) for postsurgical pain management

HBM BioVentures Quarterly Report as at 30 September 2011

Letter of HBM BioVentures to Basilea Pharmaceutica AG: Request to call an Extraordinary Shareholders Meeting

Request to call an Extraordinary Shareholders Meeting of Basilea

HBM BioVentures Investor Information

Closing of the sale of mtm laboratories to Roche

Press Release

Cathay Industrial Biotech discontinues its IPO process

Cathay Industrial Biotech announces further details for its IPO

HBM BioVentures Quarterly Report as at 30 June 2011

Cathay Industrial Biotech, third-largest portfolio position of HBM BioVentures, is planning an IPO

HBM BioVentures sells mtm laboratories, the biggest private investment in the portfolio

Shareholders´ meeting approved all proposals by the Board of Directors by a very large majority

HBM bioVentures: Annual Report 2010/2011 and invitation to the ordinary shareholders´ meeting

Invitation to the ordinary shareholders meeting

HBM BioVentures closes the operationally successful financial year 2010/2011 with loss of CHF 56 million owing to the sharp rise of the Swiss franc

Trade sale of Mpex Pharmaceuticals

HBM BioVentures: Successful sale of indirect holding in China Health System generates cash inflow of approximately USD 27 million

Closing of the sale of PharmaSwiss to Valeant

Pacira Pharmaceuticals finances itself via IPO

HBM BioVentures realises a profit of EUR 41.9 million through the sale of PharmaSwiss to Valeant

HBM BioVentures Quarterly Report as at 31 Dezember 2010

HBM BioVentures Quarterly Report as at 30 September 2010

HBM BioVentures sells its investment in Sloning

Successful sale of Asthmatx, a company from HBM BioVentures´ portfolio, to Boston Scientific increases liquidity by CHF 4 million

HBM BioVentures Quarterly Report as at 30 June 2010

HBM BioVentures’ largest public investment – Micrus – acquired by Johnson & Johnson

HBM BioVentures sells USD hedging position at a profit

Shareholders’ meeting approves all proposals by Board of Directors by large majority; Hans Peter Hasler appointed as new Chairman of the Board of Directors; Astellas, which recently acquired OSI Pharmaceuticals, will retain HBM…

Interview with Dr Andreas Wicki, CEO of HBM BioVentures

HBM BioVentures: Annual Report financial year 2009/2010 and invitation to its Shareholders´ meeting

HBM BioVentures delegates the execution of the share buy-back programme delegated to Bank Sarasin/NZB to avoid interruptions

HBM BioVentures: Invitation to the 9th Ordinary Shareholders´ Meeting

HBM BioVentures hedges some of the currency risks

HBM BioVentures closes successful 2009/2010 financial year with a profit of CHF 66 million

HBM BioVentures is 96% equity-financed after redemption of the convertible bond

HBM BioVentures Investor Information

Disclosure of shareholdings according to articles 9 and 21 of the Stock Exchange Ordinance of the Swiss Financial Market Supervisory Authority FINMAv

Disclosure of shareholdings according to articles 9 and 21 of the Stock Exchange Ordinance of the Swiss Financial Market Supervisory Authority FINMA

Disclosure of shareholdings according to articles 9 and 21 of the Stock Exchange Ordinance of the Swiss Financial Market Supervisory Authority FINMA

HBM BioVentures sells Ziemer Group investmen

Major financing round for PTC Therapeutics at 2.2 times the previous valuation

Successful IPO for China Nuokang

Financing round for Ophthotech

Disclosure of shareholdings according to articles 9 and 21 of the Stock Exchange Ordinance of the Swiss Financial Market Supervisory Authority FINMA

HBM BioVentures Quarterly Report as at 30 September 2009

Paratek Pharmaceuticals, a portfolio company of HBM BioVentures, signs licence agreement over USD 485 million

Closing of the successful sale of BRAHMS to Thermo Fisher Scientific

Successful sale of ESBATech, a Swiss company from HBM BioVentures´ portfolio, to Alcon leads to immediate NAV increase of CHF 1.75 and cash inflow of CHF 18.6 million

HBM BioVentures Ordinary Shareholders´ Meeting All Board of Directors´ proposals approved with clear majority

Disclosure of shareholdings according to articles 9 and 21 of the Stock Exchange Ordinance of the Swiss Financial Market Supervisory Authority FINMA

HBM BioVentures: Invitation to the 8th Ordinary Shareholders´ Meeting

HBM BioVentures: Agenda for the Shareholders´ Meeting

HBM BioVentures Quarterly Report as at 30 June 2009

HBM BioVentures reduces its outstanding Going Public Convertible Bond by CHF 39 million

HBM BioVentures Annual Report 2008/2009

HBM BioVentures: letter to shareholders

HBM BioVentures net asset value as at 31 March 2009

HBM BioVentures quarterly report as at 31 December 2008

HBM BioVentures holds over 5% of its own shares

Sale of private portfolio company Panomics

HBM BioVentures quarterly report as at 30 September 2008 - stable net asset value (NAV)

HBM BioVentures holds over 3% of its own shares

Disclosure of shareholdings in accordance with Articles 9 and 17 of the Federal Act of Stock Exchanges and Securities Trading - SFBC

Takeover of public portfolio company CryoCath Technologies

Share buyback - listing advertisement English

Share buyback - listing advertisement French

HBM BioVentures launches share buyback programme and resolves to make par value repayments

HBM BioVentures quarterly report as at 30 June 2008 - private portfolio boosts value

Significant cooperation agreement for portfolio company PTC Therapeutics

Annual General Meeting of HBM BioVentures Ltd - all Board of Directors proposals approved

Capital management measures to boost share appeal

Successful private portfolio positions reduce negative impact of difficult equity market climate in 2007/2008 financial year

New financing for the porfolio company PharmaSwiss - positive impact on HBM BioVentures´ net asset value (NAV) of CHF 2.90 per share

HBM BioVentures realises remaining gains on USD currency hedge positions

HBM BioVentures realises gains on USD currency hedge positions (

The first day of trading in HBM BioVentures shares on the SWX Swiss Exchange is 14 February 2008

HBM BioVentures announces further information of its planned IPO on the SWX Swiss Exchange

HBM BioVentures to apply for listing on the SWX Swiss Exchange